A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews · 2026

Read A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours by Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13421006.txt.

Description

Yin Cheong Wong and colleagues model dosing for ginisortamab, an antibody drug for solid tumours. Their dose-finding study from twenty twenty-six uses data from an early clinical trial. The drug binds gremlin-1 and restores a growth control signal. Choosing the right dose matters for the next trial stages.

Blood data came from patients receiving the drug every two weeks. Doses spanned a wide range from low to high. A two-compartment model described how the drug spreads and clears. Exposure rose in step with dose across that range. Binding to gremlin-1 in blood was also captured well. Body surface area affected how the drug distributed. Simulations from the model now guide dose selection.

Catalog record

CREATORYin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13421006

Browse the full library · About the Tower of Babel